Methylphenidate Hydrochloride Tablet, Extended Release
Product Images NDC 50268-545

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 14 technical images submitted to the FDA as part of the official labeling for Methylphenidate Hydrochloride (NDC 50268-545). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Avpak, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

18 (545 12 18mg)

18 (545 12 18mg)
This is a product label and medication guide for Methylphenidate Hydrochloride Extended-Release Tablets, a medication available only by prescription. The tablets are sold in unit dose packaging, with each containing 18mg of methylphenidate hydrochloride in a controlled-release formulation. The usual dosage is once a day, and the pharmacist is advised to provide patients with an enclosed medication guide. The tablets should be stored at controlled room temperature and away from humidity. The medication is manufactured by Avkare in Pulaski, TN.*
FDA Label Image

27 (546 12 27mg)

27 (546 12 27mg)
This is a description of Methylphenidate Hydrochloride C Extended-Release Tablets, USP, with a usual dosage of once daily. Each tablet contains 27mg of methylphenidate hydrochloride in a controlled-release formulation. The package comes with 20 tablets in a unit dose of 4 x 5, available for dispensing through prescription only. The pharmacist must dispense the enclosed Medication Guide to each patient, and the tablets should be stored at 20° to 25°C (68° to 77°). Methylphenidate is a type of medication used to treat attention deficit hyperactivity disorder (ADHD) and narcolepsy.*
FDA Label Image

36 (547 12 36mg)

36 (547 12 36mg)
Methylphenidate Hydrochloride C Extended-Release Tablets, USP 36 mg is a prescription medication used to treat attention deficit hyperactivity disorder. Each tablet contains 36 mg of methylphenidate hydrochloride in a controlled-release formulation, and the usual dosage is once a day. The medication comes in a pack of 20 tablets (4 x 5) and should be stored between 20°C to 25°C (68°F to 77°F), protected from humidity. A medication guide is enclosed to be dispensed to each patient, and the product should be kept out of reach of children. Manufactured for Avkare, Pulaski, TN 38478.*
FDA Label Image

54 (548 12 54mg)

54 (548 12 54mg)
This is a description of a medication called Methylphenidate hydrochloride, which comes in 54 mg Extended-Release Tablets. The medication is only available by prescription, and there are 20 tablets in each package. The medication guide enclosed should be given to each patient by the pharmacist and the tablets should be stored between 20° to 25°C (68° to 77°F), protected from humidity, and kept away from children. It's manufactured for AVKARE in Pulaski, TN 38478. See package insert for dosage information.*
FDA Label Image

Fig1 (Methylphenidate Fig1)

FDA Label Image

Fig2 (Methylphenidate Fig2)

FDA Label Image

Fig3 (Methylphenidate Fig3)

FDA Label Image

Structure (Methylphenidate Struct)

FDA Label Image

Tb1 (Methylphenidate Table1)

Tb1 (Methylphenidate Table1)
This text provides recommended starting doses and dose ranges for methylphenidate hydrochloride extended-release tablets based on the patient's age. It includes recommended starting doses and dose ranges for children, adolescents, and adults. In particular, the recommended starting dose for children aged 6-12 is 18 mg/day, while adolescents aged 13-17 are also recommended 18 mg/day, not to exceed 2 mg/kg/day. For adults aged 18-65, the recommended starting dose is 18 or 36 mg/day, with a dose range of 18 mg - 72 mg/day. This information may be useful for healthcare professionals prescribing medications to patients for attention deficit hyperactivity disorder (ADHD).*
FDA Label Image

T2 (Methylphenidate Table2)

FDA Label Image

Table3 (Methylphenidate Table3)

Table3 (Methylphenidate Table3)
This is a table that shows the exposure of Methylphenidate hydrochloride extended-release tablets in double-blind and open-label clinical studies. It provides information on the patient population, number of patients studied, and the dose range administered to each population. It shows that the medication was administered to 2216 children, 502 adolescents, and 1188 adults at varying doses once daily.*
FDA Label Image

Table 4 (Methylphenidate Table4)

Table 4 (Methylphenidate Table4)
Table 4 provides a breakdown of adverse reactions reported in four placebo-controlled, double-blind clinical trials of Methylphenidate Hydrochloride Extended Release tablets among children and adolescents. The table lists the percentages of subjects who reported specific adverse reactions, such as abdominal pain, dizziness, cough, and insomnia, among others. These reactions were reported by more than 1% of the treated subjects.*
FDA Label Image

Table5 (Methylphenidate Table5)

FDA Label Image

Tb 6 (Methylphenidate Table6)

Tb 6 (Methylphenidate Table6)
Table 6 shows the pharmacokinetic parameters such as Cou (ng/mL), Tinex, AUCq¢ (ngeh/mL), and ta after a single dose of Methylphenidate hydrochloride extended-release tablets in healthy adults. The parameters for a dose of 5 mg three times daily and 18 mg once daily are also included.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.